1887
Rapid communication Open Access
Like 0

Abstract

During the summer of 2023, the European Region experienced a limited resurgence of mpox cases following the substantial outbreak in 2022. This increase was characterised by asynchronous and bimodal increases, with countries experiencing peaks at different times. The demographic profile of cases during the resurgence was largely consistent with those reported previously. All available sequences from the European Region belonged to clade IIb. Sustained efforts are crucial to control and eventually eliminate mpox in the European Region.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2024.29.27.2400330
2024-07-04
2024-07-22
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2024.29.27.2400330
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/29/27/eurosurv-29-27-2.html?itemId=/content/10.2807/1560-7917.ES.2024.29.27.2400330&mimeType=html&fmt=ahah

References

  1. Vaughan AM, Cenciarelli O, Colombe S, Alves de Sousa L, Fischer N, Gossner CM, et al. A large multi-country outbreak of monkeypox across 41 countries in the WHO European Region, 7 March to 23 August 2022. Euro Surveill. 2022;27(36):2200620.  https://doi.org/10.2807/1560-7917.ES.2022.27.36.2200620  PMID: 36082686 
  2. World Health Organization (WHO). Standing recommendations for mpox issued by the Director-General of the World Health Organization (WHO) in accordance with the International Health Regulations (2005) (IHR). Geneva: WHO; 2023. Available from: https://www.who.int/publications/m/item/standing-recommendations-for-mpox-issued-by-the-director-general-of-the-world-health-organization-(who)-in-accordance-with-the-international-health-regulations-(2005)-(ihr)
  3. Delaney KP, Sanchez T, Hannah M, Edwards OW, Carpino T, Agnew-Brune C, et al. Strategies adopted by gay, bisexual, and other men who have sex with men to prevent monkeypox virus transmission - United States, August 2022. MMWR Morb Mortal Wkly Rep. 2022;71(35):1126-30.  https://doi.org/10.15585/mmwr.mm7135e1  PMID: 36048582 
  4. Brand SPC, Cavallaro M, Cumming F, Turner C, Florence I, Blomquist P, et al. The role of vaccination and public awareness in forecasts of Mpox incidence in the United Kingdom. Nat Commun. 2023;14(1):4100.  https://doi.org/10.1038/s41467-023-38816-8  PMID: 37433797 
  5. Murayama H, Pearson CAB, Abbott S, Miura F, Jung SM, Fearon E, et al. Accumulation of immunity in heavy-tailed sexual contact networks shapes mpox outbreak sizes. J Infect Dis. 2024;229(1):59-63.  https://doi.org/10.1093/infdis/jiad254  PMID: 37402631 
  6. Xiridou M, Miura F, Adam P, Op de Coul E, de Wit J, Wallinga J. The fading of the mpox outbreak among men who have sex with men: a mathematical modelling study. J Infect Dis. 2023;jiad414.  https://doi.org/10.1093/infdis/jiad414  PMID: 37740556 
  7. Haverkate MR, Willemstein IJ, van Ewijk CE, Adam PC, Lanooij SJ, Jonker-Jorna P, et al. Factors potentially contributing to the decline of the mpox outbreak in the Netherlands, 2022 and 2023. Euro Surveill. 2024;29(21):2300608.  https://doi.org/10.2807/1560-7917.ES.2024.29.21.2300608  PMID: 38785092 
  8. Mitjà O, Alemany A, Marks M, Lezama Mora JI, Rodríguez-Aldama JC, Torres Silva MS, et al. Mpox in people with advanced HIV infection: a global case series. Lancet. 2023;401(10380):939-49.  https://doi.org/10.1016/S0140-6736(23)00273-8  PMID: 36828001 
  9. Wolff Sagy Y, Zucker R, Hammerman A, Markovits H, Arieh NG, Abu Ahmad W, et al. Real-world effectiveness of a single dose of mpox vaccine in males. Nat Med. 2023;29(3):748-52.  https://doi.org/10.1038/s41591-023-02229-3  PMID: 36720271 
  10. Deputy NP, Deckert J, Chard AN, Sandberg N, Moulia DL, Barkley E, et al. Vaccine effectiveness of JYNNEOS against mpox disease in the United States. N Engl J Med. 2023;388(26):2434-43.  https://doi.org/10.1056/NEJMoa2215201  PMID: 37199451 
  11. Dalton AF, Diallo AO, Chard AN, Moulia DL, Deputy NP, Fothergill A, et al. Estimated effectiveness of JYNNEOS vaccine in preventing mpox: a multijurisdictional case-control study - United States, August 19, 2022-March 31, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(20):553-8.  https://doi.org/10.15585/mmwr.mm7220a3  PMID: 37200229 
  12. Rosenberg ES, Dorabawila V, Hart-Malloy R, Anderson BJ, Miranda W, O’Donnell T, et al. Effectiveness of JYNNEOS vaccine against diagnosed mpox infection - New York, 2022. MMWR Morb Mortal Wkly Rep. 2023;72(20):559-63.  https://doi.org/10.15585/mmwr.mm7220a4  PMID: 37339074 
  13. Bertran M, Andrews N, Davison C, Dugbazah B, Boateng J, Lunt R, et al. Effectiveness of one dose of MVA-BN smallpox vaccine against mpox in England using the case-coverage method: an observational study. Lancet Infect Dis. 2023;23(7):828-35.  https://doi.org/10.1016/S1473-3099(23)00057-9  PMID: 36924787 
  14. European Centre for Disease Prevention and Control (ECDC). Implications for the EU/EEA of the outbreak of mpox caused by Monkeypox virus clade I in the Democratic Republic of the Congo. Stockholm: ECDC; 2023; Available from: https://www.ecdc.europa.eu/en/publications-data/implications-eueea-outbreak-mpox-caused-monkeypox-virus-clade-i-democratic
  15. Kibungu EM, Vakaniaki EH, Kinganda-Lusamaki E, Kalonji-Mukendi T, Pukuta E, Hoff NA, et al. Clade I-associated mpox cases associated with sexual contact, the Democratic Republic of the Congo. Emerg Infect Dis. 2024;30(1):172-6.  https://doi.org/10.3201/eid3001.231164  PMID: 38019211 
  16. World Health Organization Regional Office for Europe (WHO/Europe). Considerations for the control and elimination of mpox in the WHO European Region update 25 April 2023: the need for integrated national operational plans. Copenhagen: WHO/Europe; 2023. Available from: https://www.who.int/europe/publications/i/item/WHO-EURO-2023-6007-45772-69163
  17. World Health Organization (WHO). Mpox strategic preparedness, readiness, and response plan: global monitoring and evaluation framework. Geneva: WHO; 2022. Available from: https://www.who.int/publications/m/item/mpox-strategic-preparedness--readiness--and-response-plan
  18. World Health Organization (WHO). Strategic framework for enhancing prevention and control of mpox- 2024-2027. Geneva: WHO; 2024. Available from: https://www.who.int/publications/i/item/9789240092907
/content/10.2807/1560-7917.ES.2024.29.27.2400330
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error